Get the Stockscreener App
0.00
100.00%
-15.02
Definium Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$15.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.48B
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
0.00
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (MNMD) Latest News
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium launches educational campaign on LSD for mental health - Investing.com
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com Nigeria
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns - Yahoo Finance
2026 Asset Growth: Why Federal Compliance Is the New Metric - thespec.com
Deinium Therapeutics (DFTX) Is Up 8.7% After Rebrand And DT120 Anxiety Pipeline UpdateWhat's Changed - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 1-Year 110% Surge? - Yahoo Finance
DFTX (Definium Therapeutics) Momentum Rank : 10 (As of Jan. 18, 2026) - GuruFocus
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress - Sahm
Definium Therapeutics stock hits 52-week high at 15.3 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 15.3 USD - Investing.com India
Five new option listings and one option delisting on January 15th - TipRanks
MNMD: DT120 targets rapid, lasting relief for anxiety and depression, with pivotal data due in 2024 - TradingView — Track All Markets
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire
Analyst Upgrade: Can Mind Medicine MindMed Inc stock reach 100 price target2025 Price Momentum & Technical Confirmation Trade Alerts - moha.gov.vn
Pullback Watch: Should I hold or sell Mind Medicine MindMed Inc stock in 2025 - moha.gov.vn
Mind Medicine MindMed : Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026 - marketscreener.com
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026 - Yahoo Finance
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 5.6%Here's What Happened - MarketBeat
Definium Therapeutics Rebrands and Highlights 2026 Pipeline - TipRanks
Definium Therapeutics (MNMD) Announces Rebranding and Ticker Cha - GuruFocus
MindMed stock soars 73% since InvestingPro’s undervalued call in May 2024 By Investing.com - Investing.com
Mind Medicine (MNMD) Stock Analysis: Massive 95% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Is Mind Medicine (MindMed) Inc. stock oversold or undervaluedQuarterly Growth Report & Verified Entry Point Detection - ulpravda.ru
What makes Mind Medicine (MindMed) Inc. (MMQ) stock appealing to growth investors2025 Volume Leaders & Daily Profit Maximizing Trade Tips - Улправда
How strong dollar benefits Mind Medicine (MindMed) Inc. (MMQ) stockTrade Volume Summary & Pattern Based Trade Signal System - ulpravda.ru
Stock Recap: Can Mind Medicine (MindMed) Inc. stock deliver surprise earnings beat2025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Mind Medicine stock hits 52-week high at $14.46 By Investing.com - Investing.com Nigeria
Assessing Mind Medicine (MNMD) Valuation After A Strong Year Of Share Price Momentum - Yahoo Finance
Mind Medicine (MindMed) (NASDAQ:MNMD) Sets New 52-Week HighStill a Buy? - MarketBeat
MindMed stock added to Needham’s Conviction List, analyst reiterates Hold By Investing.com - Investing.com Nigeria
Mind Medicine stock hits 52-week high at $14.46 - Investing.com
MindMed stock added to Needham’s Conviction List, analyst reiterates Hold - Investing.com
Mind Medicine (MNMD) Projected to Shine in 2026 with Promising D - GuruFocus
The Technical Signals Behind (MNMD) That Institutions Follow - Stock Traders Daily
Is Mind Medicine MindMed Inc a good long term investmentTrendline Breakouts & Low Cost Portfolio Growth - earlytimes.in
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.8% on Insider Selling - MarketBeat
MindMed doses first subject in Phase III Panorama study of GAD tablet - MSN
Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Daniel Karlin Sells 5,600 Shares - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Mark Sullivan Sells 11,276 Shares - MarketBeat
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? - Finviz
Definium Therapeutics Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.65%
2.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):